Tabula Rasa HealthCare, Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023013894 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.81M $26.52M
YoY Change 136.83% 116.24%
Cash & Equivalents $62.81M $26.52M
Short-Term Investments
Other Short-Term Assets $22.68M $25.02M
YoY Change -9.36% 78.24%
Inventory $8.659M $5.798M
Prepaid Expenses $3.581M $3.534M
Receivables $18.61M $20.32M
Other Receivables $19.94M $14.42M
Total Short-Term Assets $146.7M $266.3M
YoY Change -44.92% 196.7%
LONG-TERM ASSETS
Property, Plant & Equipment $19.52M $24.78M
YoY Change -21.24% -27.46%
Goodwill $115.3M $115.3M
YoY Change 0.0% -32.49%
Intangibles $35.13M $41.97M
YoY Change -16.3% -75.12%
Long-Term Investments
YoY Change
Other Assets $6.209M $4.814M
YoY Change 28.98% -1.61%
Total Long-Term Assets $209.3M $218.2M
YoY Change -4.08% -47.32%
TOTAL ASSETS
Total Short-Term Assets $146.7M $266.3M
Total Long-Term Assets $209.3M $218.2M
Total Assets $355.9M $484.5M
YoY Change -26.53% -3.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.62M $15.80M
YoY Change 30.51% 53.91%
Accrued Expenses $25.77M $20.21M
YoY Change 27.5% -18.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $57.20M
YoY Change 1360.67%
Total Short-Term Liabilities $93.69M $154.1M
YoY Change -39.21% 134.69%
LONG-TERM LIABILITIES
Long-Term Debt $321.3M $320.0M
YoY Change 0.42% -6.21%
Other Long-Term Liabilities $5.404M $1.992M
YoY Change 171.29% 193.81%
Total Long-Term Liabilities $5.404M $1.992M
YoY Change 171.29% 193.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $93.69M $154.1M
Total Long-Term Liabilities $5.404M $1.992M
Total Liabilities $434.0M $491.2M
YoY Change -11.63% 14.72%
SHAREHOLDERS EQUITY
Retained Earnings -$433.6M -$338.2M
YoY Change 28.23% 52.41%
Common Stock $3.000K $3.000K
YoY Change 0.0% 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$78.08M -$6.683M
YoY Change
Total Liabilities & Shareholders Equity $355.9M $484.5M
YoY Change -26.53% -3.86%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001651561
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37888
dei Entity Registrant Name
EntityRegistrantName
Tabula Rasa HealthCare, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5726437
dei Entity Address Address Line1
EntityAddressAddressLine1
228 Strawbridge Drive, Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Moorestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08057
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
648 - 2767
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TRHC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27054536
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62811000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70017000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
10400000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
12372000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
935000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
368000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18610000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19252000
CY2023Q2 us-gaap Inventory Net
InventoryNet
8659000
CY2022Q4 us-gaap Inventory Net
InventoryNet
6566000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3581000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4664000
CY2023Q2 trhc Client Claims Receivable Current
ClientClaimsReceivableCurrent
16415000
CY2022Q4 trhc Client Claims Receivable Current
ClientClaimsReceivableCurrent
16377000
CY2023Q2 trhc Receivable With Imputed Interest Net Amount After Allowance For Credit Loss Current
ReceivableWithImputedInterestNetAmountAfterAllowanceForCreditLossCurrent
3527000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
22678000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18187000
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
22825000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
146681000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
170260000
CY2023Q2 trhc Property Plant And Equipment And Finance Lease Right Of Use Asset Excluding Computer Software Development Cost After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetExcludingComputerSoftwareDevelopmentCostAfterAccumulatedDepreciationAndAmortization
9369000
CY2022Q4 trhc Property Plant And Equipment And Finance Lease Right Of Use Asset Excluding Computer Software Development Cost After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetExcludingComputerSoftwareDevelopmentCostAfterAccumulatedDepreciationAndAmortization
9158000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10149000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10483000
CY2023Q2 trhc Capitalized Software Development Costs Net
CapitalizedSoftwareDevelopmentCostsNet
33077000
CY2022Q4 trhc Capitalized Software Development Costs Net
CapitalizedSoftwareDevelopmentCostsNet
32592000
CY2023Q2 us-gaap Goodwill
Goodwill
115323000
CY2022Q4 us-gaap Goodwill
Goodwill
115323000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
35129000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
38326000
CY2022Q4 trhc Contingent Consideration Receivable Long Term Fair Value Disclosure
ContingentConsiderationReceivableLongTermFairValueDisclosure
3350000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6209000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4657000
CY2023Q2 us-gaap Assets
Assets
355937000
CY2022Q4 us-gaap Assets
Assets
384149000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2982000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2708000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
20623000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19459000
CY2023Q2 trhc Client Claims Payable Current
ClientClaimsPayableCurrent
10981000
CY2022Q4 trhc Client Claims Payable Current
ClientClaimsPayableCurrent
10781000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
59105000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
55745000
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
13389000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
93691000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
102082000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12102000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12786000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1507000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1380000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5404000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4298000
CY2023Q2 us-gaap Liabilities
Liabilities
434016000
CY2022Q4 us-gaap Liabilities
Liabilities
441180000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28360785
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28031616
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27058420
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27129096
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1302365
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
902520
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
4049000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3391000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
359573000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
354214000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-433606000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-407857000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-78079000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-57031000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355937000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
384149000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90036000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72597000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
178313000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
139707000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
67507000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
56631000
us-gaap Cost Of Revenue
CostOfRevenue
135031000
us-gaap Cost Of Revenue
CostOfRevenue
109352000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1777000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3243000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3056000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7208000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2732000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2172000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5185000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4821000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17599000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15150000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34176000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31028000
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-3350000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-3750000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
4062000
CY2023Q2 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
6103000
CY2022Q2 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
5489000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
12303000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
11231000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
31561000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
26054000
us-gaap Operating Expenses
OperatingExpenses
58470000
us-gaap Operating Expenses
OperatingExpenses
58350000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9032000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10088000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15188000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27995000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1144000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2444000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2409000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-4713000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
566000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1018000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-578000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2444000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1391000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4713000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9610000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12532000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16579000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32708000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
133000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
159000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
238000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
375000
CY2023Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-9743000
CY2022Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-12691000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-16817000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-33083000
CY2023Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-108000
CY2022Q2 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-36919000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-8932000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-44720000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9851000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49610000
us-gaap Net Income Loss
NetIncomeLoss
-25749000
us-gaap Net Income Loss
NetIncomeLoss
-77803000
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.38
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.38
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.53
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.53
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.66
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.66
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.38
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.38
CY2022Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-1.54
CY2022Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-1.54
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-0.35
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.35
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-1.87
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-1.87
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.07
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
54000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-514000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2979000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2093000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
354000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3829000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7916000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.25
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25422032
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25422032
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23959726
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23959726
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25333137
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25333137
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23913050
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23913050
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-57031000
CY2023Q1 trhc Stock Issued During Period Value Stock Options Exercised Cashless Exercise
StockIssuedDuringPeriodValueStockOptionsExercisedCashlessExercise
219000
CY2023Q1 trhc Share Based Payment Arrangement Equity Instruments Other Than Options Decrease For Tax Withholding Obligation
ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsDecreaseForTaxWithholdingObligation
622000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2468000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-15898000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-70864000
CY2023Q2 trhc Stock Issued During Period Value Stock Options Exercised Cashless Exercise
StockIssuedDuringPeriodValueStockOptionsExercisedCashlessExercise
-98000
CY2023Q2 trhc Share Based Payment Arrangement Equity Instruments Other Than Options Decrease For Tax Withholding Obligation
ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsDecreaseForTaxWithholdingObligation
36000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2770000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-9851000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-78079000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
55756000
CY2022Q1 trhc Stock Issued During Period Value Stock Options Exercised Cashless Exercise
StockIssuedDuringPeriodValueStockOptionsExercisedCashlessExercise
60000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8609000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-28193000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
36232000
CY2022Q2 trhc Stock Issued During Period Value Stock Options Exercised Cashless Exercise
StockIssuedDuringPeriodValueStockOptionsExercisedCashlessExercise
3000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
6692000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49610000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-6683000
us-gaap Profit Loss
ProfitLoss
-25749000
us-gaap Profit Loss
ProfitLoss
-77803000
trhc Depreciation Amortization And Accretion Net Total Including Discontinued Operations
DepreciationAmortizationAndAccretionNetTotalIncludingDiscontinuedOperations
12303000
trhc Depreciation Amortization And Accretion Net Total Including Discontinued Operations
DepreciationAmortizationAndAccretionNetTotalIncludingDiscontinuedOperations
18562000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
678000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
939000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
127000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-368000
trhc Share Based Payment Arrangement Expense Including Discontinued Operations
ShareBasedPaymentArrangementExpenseIncludingDiscontinuedOperations
5238000
trhc Share Based Payment Arrangement Expense Including Discontinued Operations
ShareBasedPaymentArrangementExpenseIncludingDiscontinuedOperations
15301000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-3750000
trhc Asset Impairment Charges Total Including Discontinued Operations
AssetImpairmentChargesTotalIncludingDiscontinuedOperations
363000
trhc Asset Impairment Charges Total Including Discontinued Operations
AssetImpairmentChargesTotalIncludingDiscontinuedOperations
40510000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-4888000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-292000
trhc Increase Decrease In Client Claims Receivables
IncreaseDecreaseInClientClaimsReceivables
38000
trhc Increase Decrease In Client Claims Receivables
IncreaseDecreaseInClientClaimsReceivables
3162000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
769000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1222000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
9295000
trhc Increase Decrease In Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
374000
trhc Increase Decrease In Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities
9188000
trhc Increase Decrease In Client Claims Payables
IncreaseDecreaseInClientClaimsPayables
200000
trhc Increase Decrease In Client Claims Payables
IncreaseDecreaseInClientClaimsPayables
353000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
554000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2139000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3647000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8840000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1310000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
471000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
7187000
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
17870000
us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
3384000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5113000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18341000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
219000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
655000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
350000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
27700000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-436000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27410000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9196000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17909000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
82407000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15706000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73211000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33615000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2762000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2693000
trhc Capital Expenditures Vendor Financing Arrangements
CapitalExpendituresVendorFinancingArrangements
881000
us-gaap Interest Paid Net
InterestPaidNet
2844000
us-gaap Interest Paid Net
InterestPaidNet
3882000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
30000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
137000
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
24000
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
202000
trhc Employee Taxes For Shares Withheld But Not Yet Paid
EmployeeTaxesForSharesWithheldButNotYetPaid
3000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62811000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26522000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
10400000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
7062000
CY2022Q2 us-gaap Cash Including Discontinued Operations
CashIncludingDiscontinuedOperations
31000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73211000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33615000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1.      Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Tabula Rasa HealthCare, Inc. (the “Company”) is a healthcare technology company enabling simplified and individualized care that improves the health of those the Company serves. The Company offers comprehensive pharmacy services that include personalized, precision medication management and delivery, as well as a suite of clinical and business management tools that help health plans and at-risk provider groups optimize utilization and improve patient health.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 trhc Capitalized Implementation Costs Cloud Computing
CapitalizedImplementationCostsCloudComputing
2178000
CY2022Q4 trhc Capitalized Implementation Costs Cloud Computing
CapitalizedImplementationCostsCloudComputing
2158000
CY2023Q2 trhc Accumulated Amortization Cloud Computing Implementation Costs
AccumulatedAmortizationCloudComputingImplementationCosts
775000
CY2022Q4 trhc Accumulated Amortization Cloud Computing Implementation Costs
AccumulatedAmortizationCloudComputingImplementationCosts
590000
CY2023Q2 trhc Amortization Of Cloud Computing Implementation Costs
AmortizationOfCloudComputingImplementationCosts
63000
CY2022Q2 trhc Amortization Of Cloud Computing Implementation Costs
AmortizationOfCloudComputingImplementationCosts
52000
trhc Amortization Of Cloud Computing Implementation Costs
AmortizationOfCloudComputingImplementationCosts
185000
trhc Amortization Of Cloud Computing Implementation Costs
AmortizationOfCloudComputingImplementationCosts
105000
CY2023Q2 trhc Receivable With Imputed Interest Allowance For Credit Loss
ReceivableWithImputedInterestAllowanceForCreditLoss
149000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(g)</b></span><b style="font-weight:bold;">Concentrations of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is subject to concentrations of credit risk related to cash, cash equivalents, restricted cash, accounts receivable, and client claims receivable. While the Company maintains its cash, cash equivalents and restricted cash with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash, cash equivalents or restricted cash to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s medication fulfillment services clients are sponsors of the federal Medicare Part D plan (prescription drug coverage plan) and, therefore, subject to the payment regulations established by the Centers for Medicare &amp; Medicaid Services (“CMS”). Under CMS guidelines, Medicare Part D sponsors are required to remit payment for claims within 14 calendar days of the date on which an electronically submitted claim is received and within 30 days of the date on which non-electronically-submitted claims are received. The Company extends credit to clients based upon such terms, as well as management’s evaluation of creditworthiness, and generally collateral is not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s clients also include health plans and other healthcare providers. Credit associated with these accounts is extended based upon management’s evaluation of creditworthiness and is monitored on an on-going basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of June 30, 2023 and December 31, 2022, no client represented more than 10% of net accounts receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of June 30, 2023, one client represented 18% of client claims receivable. As of December 31, 2022, one client represented 14% of client claims receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">One client accounted for 13% and 16% of total revenue for the three months ended June 30, 2023 and 2022, respectively, and 13% and 17% of total revenue for the six months ended June 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2022Q2 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-12691000
CY2022Q2 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
-12691000
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-16817000
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
-16817000
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-33083000
us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
-33083000
CY2023Q2 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
-108000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90036000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72597000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
178313000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
139707000
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
18389000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
15115000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2767000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3435000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
15115000
trhc Contract With Customer Asset Cash Received
ContractWithCustomerAssetCashReceived
15393000
trhc Contract With Customer Asset Change In Estimate
ContractWithCustomerAssetChangeInEstimate
820000
trhc Contract With Customer Asset Change Excluding Reclassification To Receivable
ContractWithCustomerAssetChangeExcludingReclassificationToReceivable
17847000
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
18389000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3435000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2481000
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
1813000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2767000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1810000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2191000
CY2023Q2 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-9743000
CY2023Q2 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Diluted
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
-9743000
CY2023Q2 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
-108000
CY2022Q2 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
-36919000
CY2022Q2 us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
-36919000
us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
-8932000
us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
-8932000
us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Basic
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
-44720000
us-gaap Net Income Loss From Discontinued Operations Available To Common Shareholders Diluted
NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
-44720000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9851000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9851000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49610000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-49610000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25749000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25749000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-77803000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-77803000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25422032
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25422032
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23959726
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23959726
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25333137
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25333137
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23913050
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23913050
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.38
CY2023Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.38
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.53
CY2022Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.53
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.66
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.66
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.38
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.38
CY2022Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-1.54
CY2022Q2 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-1.54
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-0.35
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.35
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-1.87
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-1.87
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.07
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.25
CY2023Q2 trhc Receivable With Imputed Interest Allowance For Credit Loss
ReceivableWithImputedInterestAllowanceForCreditLoss
149000
CY2023Q2 trhc Receivable With Imputed Interest Net Amount After Allowance For Credit Loss Noncurrent
ReceivableWithImputedInterestNetAmountAfterAllowanceForCreditLossNoncurrent
1505000
CY2023Q2 us-gaap Receivable With Imputed Interest Net Amount
ReceivableWithImputedInterestNetAmount
5181000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
38326000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1598000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1695000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12510008
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13065820
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
18389000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
15115000
CY2023Q2 trhc Contingent Consideration Receivable Current Fair Value Disclosure
ContingentConsiderationReceivableCurrentFairValueDisclosure
100000
CY2023Q2 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
445000
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
719000
CY2023Q2 trhc Other Miscellaneous Assets Current
OtherMiscellaneousAssetsCurrent
3744000
CY2022Q4 trhc Other Miscellaneous Assets Current
OtherMiscellaneousAssetsCurrent
2353000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
22678000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18187000
CY2023Q1 trhc Receivable With Imputed Interest Allowance For Credit Loss
ReceivableWithImputedInterestAllowanceForCreditLoss
151000
trhc Receivable With Imputed Interest Allowance For Credit Loss Increase Decrease Amount
ReceivableWithImputedInterestAllowanceForCreditLossIncreaseDecreaseAmount
-2000
CY2023Q2 trhc Receivable With Imputed Interest Allowance For Credit Loss Increase Decrease Amount
ReceivableWithImputedInterestAllowanceForCreditLossIncreaseDecreaseAmount
-2000
CY2023Q2 trhc Receivable With Imputed Interest Net Amount Current
ReceivableWithImputedInterestNetAmountCurrent
3527000
CY2023Q2 trhc Receivable With Imputed Interest Net Amount After Allowance For Credit Loss Current
ReceivableWithImputedInterestNetAmountAfterAllowanceForCreditLossCurrent
3527000
CY2023Q2 trhc Receivable With Imputed Interest Net Amount Noncurrent
ReceivableWithImputedInterestNetAmountNoncurrent
1654000
CY2023Q2 trhc Receivable With Imputed Interest Allowance For Credit Loss
ReceivableWithImputedInterestAllowanceForCreditLoss
149000
CY2023Q2 trhc Receivable With Imputed Interest Net Amount After Allowance For Credit Loss Total
ReceivableWithImputedInterestNetAmountAfterAllowanceForCreditLossTotal
5032000
trhc Receivable With Imputed Interest Allowance For Credit Loss Provision Amount
ReceivableWithImputedInterestAllowanceForCreditLossProvisionAmount
151000
trhc Receivable With Imputed Interest Allowance For Credit Loss Increase Decrease Amount
ReceivableWithImputedInterestAllowanceForCreditLossIncreaseDecreaseAmount
-2000
CY2023Q2 trhc Receivable With Imputed Interest Allowance For Credit Loss
ReceivableWithImputedInterestAllowanceForCreditLoss
149000
CY2023Q2 trhc Capitalized Software Development Costs Gross
CapitalizedSoftwareDevelopmentCostsGross
62729000
CY2022Q4 trhc Capitalized Software Development Costs Gross
CapitalizedSoftwareDevelopmentCostsGross
54853000
CY2023Q2 trhc Capitalized Software Development Costs Accumulated Amortization
CapitalizedSoftwareDevelopmentCostsAccumulatedAmortization
29652000
CY2022Q4 trhc Capitalized Software Development Costs Accumulated Amortization
CapitalizedSoftwareDevelopmentCostsAccumulatedAmortization
22261000
CY2023Q2 trhc Capitalized Software Development Costs Net
CapitalizedSoftwareDevelopmentCostsNet
33077000
CY2022Q4 trhc Capitalized Software Development Costs Net
CapitalizedSoftwareDevelopmentCostsNet
32592000
CY2023Q2 trhc Capitalized Computer Software Not Yet Subject To Amortization
CapitalizedComputerSoftwareNotYetSubjectToAmortization
8246000
CY2022Q4 trhc Capitalized Computer Software Not Yet Subject To Amortization
CapitalizedComputerSoftwareNotYetSubjectToAmortization
4997000
CY2023Q2 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
3715000
CY2022Q2 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
2581000
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
7390000
us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
5781000
trhc Impairment Of Software Development Costs
ImpairmentOfSoftwareDevelopmentCosts
4062000
CY2023Q2 us-gaap Goodwill
Goodwill
115323000
CY2022Q4 us-gaap Goodwill
Goodwill
115323000
CY2023Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
69023000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
33894000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
35129000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
69023000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
30697000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3197000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3389000
CY2023Q2 trhc Accrued Professional Fees And Contract Labor
AccruedProfessionalFeesAndContractLabor
2605000
CY2022Q4 trhc Accrued Professional Fees And Contract Labor
AccruedProfessionalFeesAndContractLabor
751000
CY2023Q2 trhc Consideration Payable To Customers Current
ConsiderationPayableToCustomersCurrent
24015000
CY2022Q4 trhc Consideration Payable To Customers Current
ConsiderationPayableToCustomersCurrent
20311000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.39
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
138715
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2685000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4684000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4466000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4338000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4271000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3681000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
11004000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
35129000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10257000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10780000
CY2023Q2 trhc Contract With Customer Liability Excluding Customer Deposits Current
ContractWithCustomerLiabilityExcludingCustomerDepositsCurrent
2311000
CY2022Q4 trhc Contract With Customer Liability Excluding Customer Deposits Current
ContractWithCustomerLiabilityExcludingCustomerDepositsCurrent
3309000
CY2023Q2 trhc Contract With Customer Liability Customer Deposits Current
ContractWithCustomerLiabilityCustomerDepositsCurrent
904000
CY2022Q4 trhc Contract With Customer Liability Customer Deposits Current
ContractWithCustomerLiabilityCustomerDepositsCurrent
904000
CY2023Q2 trhc Client Funds Obligations
ClientFundsObligations
10400000
CY2022Q4 trhc Client Funds Obligations
ClientFundsObligations
12372000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
2133000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2133000
CY2023Q2 trhc Vendor Financing Arrangements Current
VendorFinancingArrangementsCurrent
627000
CY2022Q4 trhc Vendor Financing Arrangements Current
VendorFinancingArrangementsCurrent
568000
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
106000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
8000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5747000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4609000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
59105000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
55745000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
133000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
159000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.014
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.014
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.013
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.013
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
238000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
375000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.014
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.014
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1177805
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
240194
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
29.63
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
798896
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y3M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
96000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
798896
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
32.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
96000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
798434
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
32.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
96000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
458000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
219000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
131330
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
658000
CY2023Q2 trhc Share Based Payment Arrangement Expense Including Discontinued Operations
ShareBasedPaymentArrangementExpenseIncludingDiscontinuedOperations
2770000
CY2022Q2 trhc Share Based Payment Arrangement Expense Including Discontinued Operations
ShareBasedPaymentArrangementExpenseIncludingDiscontinuedOperations
6692000
trhc Share Based Payment Arrangement Expense Including Discontinued Operations
ShareBasedPaymentArrangementExpenseIncludingDiscontinuedOperations
5238000
trhc Share Based Payment Arrangement Expense Including Discontinued Operations
ShareBasedPaymentArrangementExpenseIncludingDiscontinuedOperations
15301000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
3350000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
500000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
-3750000
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
100000

Files In Submission

Name View Source Status
0001558370-23-013894-index-headers.html Edgar Link pending
0001558370-23-013894-index.html Edgar Link pending
0001558370-23-013894.txt Edgar Link pending
0001558370-23-013894-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trhc-20230630.xsd Edgar Link pending
trhc-20230630x10q.htm Edgar Link pending
trhc-20230630xex10d5.htm Edgar Link pending
trhc-20230630xex10d6.htm Edgar Link pending
trhc-20230630xex31d1.htm Edgar Link pending
trhc-20230630xex31d2.htm Edgar Link pending
trhc-20230630xex32d1.htm Edgar Link pending
trhc-20230630_def.xml Edgar Link unprocessable
trhc-20230630_lab.xml Edgar Link unprocessable
trhc-20230630_pre.xml Edgar Link unprocessable
trhc-20230630x10q_htm.xml Edgar Link completed
trhc-20230630_cal.xml Edgar Link unprocessable